From the Department of Biological Sciences, Louisiana State University, Baton Rouge, Louisiana 70803 and.
J Biol Chem. 2014 Mar 21;289(12):8562-9. doi: 10.1074/jbc.M113.543777. Epub 2014 Feb 4.
Atherosclerosis is associated with chronic inflammation occurring over decades. The enzyme 15-lipoxygenase-2 (15-LOX-2) is highly expressed in large atherosclerotic plaques, and its activity has been linked to the progression of macrophages to the lipid-laden foam cells present in atherosclerotic plaques. We report here the crystal structure of human 15-LOX-2 in complex with an inhibitor that appears to bind as a substrate mimic. 15-LOX-2 contains a long loop, composed of hydrophobic amino acids, which projects from the amino-terminal membrane-binding domain. The loop is flanked by two Ca(2+)-binding sites that confer Ca(2+)-dependent membrane binding. A comparison of the human 15-LOX-2 and 5-LOX structures reveals similarities at the active sites, as well striking differences that can be exploited for design of isoform-selective inhibitors.
动脉粥样硬化与数十年的慢性炎症有关。酶 15-脂氧合酶-2(15-LOX-2)在大型动脉粥样硬化斑块中高度表达,其活性与巨噬细胞向存在于动脉粥样硬化斑块中的富含脂质的泡沫细胞的进展有关。我们在这里报告了人 15-LOX-2 与一种抑制剂的复合物的晶体结构,该抑制剂似乎作为底物类似物结合。15-LOX-2 包含一个由疏水性氨基酸组成的长环,从氨基末端膜结合域伸出。该环由两个 Ca2+结合位点侧翼,赋予 Ca2+依赖性膜结合。人 15-LOX-2 和 5-LOX 结构的比较揭示了活性位点的相似性,以及可以用于设计同工酶选择性抑制剂的惊人差异。